NCT05607680

A Study of IBI362 in Participants With Obesity or Overweight

A Randomized, Double-blind, Placebo-controlled Phase III Study Evaluating the Efficacy and Safety of IBI362 in Chinese Participants With Obesity or Overweight (GLORY-1)

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 610 (actual)
• Sponsor: Innovent Biologics (Suzhou) Co. Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study evaluating the efficacy and safety of IBI362 in overweight or obese subjects. Subjects will be randomly assigned to IBI362 low-dose, high-dose and placebo groups. The entire trial cycle includes a 2-week screening period, a 48-week double-blind treatment period, and a 12-week drug withdrawal follow-up period after the end of treatment.

Conditions

• Obesity Or Overweight

Interventions

Type	Name	Description
DRUG	Placebo	Placebo administered subcutaneously (SC) once a week.
DRUG	IBI362	IBI362 administered subcutaneously (SC) once a week.

Timeline

• Start date: 2022-11-14
• Primary completion: 2023-08-21
• Completion: 2024-04-16
• First posted: 2022-11-07
• Last updated: 2024-11-12

Locations

23 sites across 1 country: China